Skip to content
Catalyst
Search

Papers/PMID:22112804

Long-term follow-up for mortality and cancer in a randomized placebo-controlled trial of vitamin D(3) and/or calcium (RECORD trial).

The Journal of clinical endocrinology and metabolism2012The record

2 findings · 1 compound · 2 endpoints · 2 null

What it reported

How to read these marks

Every finding here is a null result.

What did not

2 findings

  • calciol — no detected effect on all-site cancer incidence

    Evidence strength: very limited.FindingNull result
    “In intention-to-treat analyses, mortality [hazard ratio (HR) = 0.93; 95% confidence interval (CI) = 0.85-1.02], vascular disease mortality (HR = 0.91; 95% CI = 0.79-1.05), cancer mortality (HR = 0.85; 95% CI = 0.68-1.06), and cancer incidence (HR = 1.07; 95% CI = 0.92-1.25) did not differ significantly between participants allocated vitamin D and those not.”
    Quoted verbatim from Long-term follow-up for mortality and cancer in a randomized placebo-controlled trial of vitamin D(3) and/or calcium (RECORD trial)..
    Study
    RCT
    Dose
    vitamin D3 800 IU daily
    Population
    People aged at least 70 years with previous low-trauma fracture; 2x2 factorial, vitamin D3 versus no vitamin D3 (calcium allocation balanced across the comparison); follow-up 3 years after 24-62 months of treatment

    Effect 1.07 hazard ratio, 95% CI 0.92 to 1.25

    Long-term follow-up for mortality and cancer in a randomized placebo-controlled trial of vitamin D(3) and/or calcium (RECORD trial).2012PMID:2211280410.1210/jc.2011-1309Permalink

  • calciol — no detected effect on all-cause mortality

    Evidence strength: very limited.FindingNull resultreplicated ×5
    “In intention-to-treat analyses, mortality [hazard ratio (HR) = 0.93; 95% confidence interval (CI) = 0.85-1.02], vascular disease mortality (HR = 0.91; 95% CI = 0.79-1.05), cancer mortality (HR = 0.85; 95% CI = 0.68-1.06), and cancer incidence (HR = 1.07; 95% CI = 0.92-1.25) did not differ significantly between participants allocated vitamin D and those not.”
    Quoted verbatim from Long-term follow-up for mortality and cancer in a randomized placebo-controlled trial of vitamin D(3) and/or calcium (RECORD trial)..
    Study
    RCT
    Dose
    vitamin D3 800 IU daily
    Population
    People aged at least 70 years with previous low-trauma fracture; 2x2 factorial, vitamin D3 versus no vitamin D3 (calcium allocation balanced across the comparison); follow-up 3 years after 24-62 months of treatment

    Effect 0.93 hazard ratio, 95% CI 0.85 to 1.02

    Long-term follow-up for mortality and cancer in a randomized placebo-controlled trial of vitamin D(3) and/or calcium (RECORD trial).2012PMID:2211280410.1210/jc.2011-1309Permalink